Tagged with Rare Disease

Austria Dr. Wolfgang Schnitzel, general manager of Shire Austria, and Karl-Heinz Hofbauer, site lead Vienna and managing director for the Technical Operations business, discuss the huge impact of Shire’s 32 billion USD acquisition of Baxalta that has grown the workforce from a few Shire employees in Austria to 3,500. Furthermore, they…

Colombia Gianfranco Biliotti, recently appointed General Manager for Alexion Colombia, shares his insights on the particularities of operating in the ultra-rare disease segment, while highlighting the importance of managerial flexibility, the company’s unmatched patient-centricity and close ties with doctors, the role of education in improving patients’ lives and his strategic priorities…

Greece A strong proponent of the value of orphan drugs, Shire Greece’s Managing Director, Christos Dakas, shares his insights on the recent merger with Baxalta, the necessity of exempting orphan and haemophilia drugs from clawbacks to circumvent market challenges for critical treatments, as well as his vision for the bright future…

Ireland James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years. James,…

Switzerland Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region.   Since day one, Alexion’s mission has been to focus solely on discovering treatments for patients affected by these incredibly rare…

Mexico Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to further accelerate the growth and consolidate the strategic positioning of Shire, a company that now proudly stands out as the…

Switzerland Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s business and remains a key part of their DNA; and how a focus on patient centricity remains at the core…

Slovakia Biogen Slovakia’s Country Director on being an innovative global biotech in Slovakia, market access in the country, and the company’s commitment to improving the lives of patients through MS, Alzheimer’s and rare disease treatments. Ms. Strapkova Boydova, you have been Country Director of Biogen Slovakia since its inception in 2006.…

Ireland Julie O’Neill, Alexion’s EVP for Global Operations highlights Alexion’s establishment of its Global Supply Chain headquarters in Dublin, Ireland, its investment in Athlone, her thoughts on the opportunities and challenges in the Irish pharmaceutical landscape, and her vision for Alexion. Alexion first established a manufacturing presence in Dublin, Ireland in…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative medicines to patients with rare diseases and other specialty conditions. Could you please start by describing the company’s engagement with…

Pharma Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager for Benelux shares the plans of the company for the Netherlands and Benelux, how Sobi is transforming its product portfolio,…